Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Tiering and cross-region replication for S3 Tables to automate cost optimization and data availability for Apache Iceberg ...
News headlines Recursion Pharmaceuticals (RXRX) is gaining attention due to positive clinical trial results for its drug REC-4881 and a recent upgrade by JPMorgan. Cathie Wood's ARK Investment also ...
Bun 1.3 revolutionizes full-stack JavaScript development with unified database APIs and zero-config frontend setup.
DNA Ginkgo Bioworks Holdings, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback